Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-10-30 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司章程（2023年10月修订）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 金宇生物技术股份有限公司, revised in October 2023. It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, management, shareholder meetings, share issuance, share transfer, financial accounting, profit distribution, auditing, and other governance matters. The content is a comprehensive governance document outlining internal rules and procedures for the company and its shareholders. It is not a financial report, earnings release, or announcement. It is not a proxy statement or voting results announcement. It is not a regulatory filing or legal proceeding update. The document fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-10-30 Chinese
金宇生物技术股份有限公司董事会议事规则（2023年10月修订）
Governance Information Classification · 95% confidence The document is titled "董事会议事规则" which translates to "Rules of Procedure for the Board of Directors". It details the governance structure, qualifications, duties, rights, meeting procedures, decision-making processes, and other operational rules for the company's board of directors. There is no financial data, audit information, or report content. Instead, it focuses on internal governance and board management practices. This matches the description of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices. The document length is substantial and contains detailed governance rules, not a brief announcement or a report publication notice. Therefore, the appropriate classification is CGR with high confidence.
2023-10-30 Chinese
金宇生物技术股份有限公司董事会薪酬与考核委员会实施细则（2023年10月修订）
Governance Information Classification · 95% confidence The document is titled as the implementation rules for the Board of Directors' Remuneration and Assessment Committee of a company. It details the committee's establishment, responsibilities, membership, decision-making procedures, and governance related to remuneration and performance evaluation of directors and senior management. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, no earnings release, and no investor presentation. The document is a governance-related internal rules document about board committee structure and procedures, specifically about remuneration and assessment. This fits the definition of Governance Information (CGR). The document length is 2821 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Therefore, the classification is CGR with high confidence.
2023-10-30 Chinese
金宇生物技术股份有限公司第十一届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 11th Board of Directors' 11th meeting of 金宇生物技术股份有限公司 (Jinyu Biotechnology Co., Ltd.). It includes approval of the company's 2023 Q3 report, amendments to company bylaws and board rules, and changes to the audit committee membership. The document does not contain the full quarterly report or detailed financial statements but references that the full 2023 Q3 report is disclosed on the Shanghai Stock Exchange website. The document is relatively short (1614 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it is best classified as Board/Management Information (MANG), which covers announcements of changes in board or senior management and related board meeting resolutions.
2023-10-30 Chinese
金宇生物技术股份有限公司第十一届监事会第十次会议决议公告
Report Publication Announcement Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the review and approval of the company's 2023 third quarter report. It states that the Supervisory Board has audited the 2023 Q3 report and expresses their opinion on its compliance and accuracy. However, the actual 2023 third quarter report is not included in the document; instead, it refers readers to the full report published on the Shanghai Stock Exchange website. The document length is short (764 characters), and it primarily serves as an announcement of the Supervisory Board's approval of the interim report rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the Interim/Quarterly Report (IR) itself.
2023-10-30 Chinese
金宇生物技术股份有限公司关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's Articles of Association (公司章程). It details changes to governance-related provisions such as board member qualifications, duties, and committee structures. The document is a formal public notice of these amendments and states that the revised Articles will be subject to shareholder approval. There are no financial statements, audit results, or earnings data presented. The content focuses on governance rules and board-related matters, which aligns with governance information filings. The document length is relatively short (2742 characters), and it is not a full report but an announcement of changes to governance documents. Therefore, the most appropriate classification is Governance Information (CGR).
2023-10-30 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.